Literature DB >> 6188910

Relaxation of large coronary artery by verapamil, D600, and nifedipine is constrictor selective: comparison with glyceryl trinitrate.

J A Angus, R M Brazenor.   

Abstract

We compared the vasodilator potencies of a number of Ca2+-entry blockers with glyceryl trinitrate (GTN) in isolated ring segments of dog coronary arteries contracted by a variety of substances. Rings were contracted to 80% of maximum by serotonin, phenylephrine (PE), noradrenaline (NA), K+ (KCl), or U46619 (stable thromboxane A2 analogue). Cumulative additions of a vasodilator then relaxed the ring towards basal tone. GTN had a similar IC50 value (0.1 - 0.3 microM) regardless of the substance used to contract the ring. In contrast, nifedipine and verapamil were weak relaxant drugs against arteries contracted by U46619. Nifedipine was most potent in rings contracted by K+, whereas verapamil was similarly effective towards K+ and serotonin, but threefold less potent against PE or NA. The (-)enantiomers of verapamil and D600 were more potent (seven-to 26-fold) than the (+)enantiomers in arteries contracted by K+ or serotonin, but not for PE or NA. A combination of (-)verapamil and GTN showed additive effects without a change in the IC50 for GTN. We conclude that, in contrast with GTN, the effectiveness of Ca2+-entry blockers in the treatment of coronary vasospasm may be dependent on the nature of the constrictor signal.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6188910     DOI: 10.1097/00005344-198303000-00026

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

1.  Alpha 2-adrenoceptors and endothelium-dependent relaxation in canine large arteries.

Authors:  J A Angus; T M Cocks; K Satoh
Journal:  Br J Pharmacol       Date:  1986-08       Impact factor: 8.739

2.  The half-life of endothelium-derived relaxing factor released from bovine aortic endothelial cells in culture.

Authors:  J A Angus; T M Cocks
Journal:  J Physiol       Date:  1987-07       Impact factor: 5.182

3.  Evidence for mediation by endothelium-derived hyperpolarizing factor of relaxation to bradykinin in the bovine isolated coronary artery independently of voltage-operated Ca2+ channels.

Authors:  G R Drummond; T M Cocks
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  Differing calcium sensitivities of human cerebral and digital arteries, human metatarsal veins, and rat aorta.

Authors:  V Iwanov; R F Moulds
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

5.  Comparison of contractile responses to 5-hydroxytryptamine and sumatriptan in human isolated coronary artery: synergy with the thromboxane A2-receptor agonist, U46619.

Authors:  T M Cocks; B K Kemp; D Pruneau; J A Angus
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

6.  Enhanced vasocontraction of rat tail arteries by toxoflavin.

Authors:  Z Wang; M Ma; R Wang
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

7.  Stereoisomers of calcium antagonists discriminate between coronary vascular and myocardial sites.

Authors:  F T van Amsterdam; J Zaagsma
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-02       Impact factor: 3.000

8.  Pharmacological reactivity of human epicardial coronary arteries: phasic and tonic responses to vasoconstrictor agents differentiated by nifedipine.

Authors:  A P Stork; T M Cocks
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

9.  Baroreflex resetting but no vascular tolerance in response to transdermal glyceryl trinitrate in conscious rabbits.

Authors:  A P Serone; J A Angus; C E Wright
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

10.  Nicorandil as a nitrate, and cromakalim as a potassium channel opener, dilate isolated porcine large coronary arteries in an agonist-nonselective manner.

Authors:  K Satoh; T Mori; H Yamada; N Taira
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.